GEN Exclusives

More »

GEN News Highlights

More »
Sep 7, 2010

Roche and reMynd Partner to Develop Disease-Modifying AD and PD Candidates

Roche and reMynd Partner to Develop Disease-Modifying AD and PD Candidates

Swiss drugs giant retains rights to commercialize neurotoxicity-targeting products.

  • Roche is teaming up with Belgian firm reMynd to develop the latter’s preclinical-stage small molecule drug candidates targeting the α-synuclein and tau-related toxicities involved in Parkinson and Alzheimer diseases. reMynd claims the deal could be worth up to Euro 500,000 (about $636,000) in milestone payments from Roche, even before sales royalties.

    The collaboration will involve the two firms establishing joint research teams, with Roche providing chemistry, lead-optimization, and preclinical development expertise, and reMynd carrying out nonclinical pharmacology studies and further research to unpick the underlying molecular mechanisms. Roche will take on all clinical development and worldwide commercialization of relevant products. 

    ReMynd claims its candidates are designed to inhibit the mechanisms of neurotoxicity involved in both these diseases, rather than just address the resulting symptoms. “Our most advanced compound in Parkinson’s disease has demonstrated full inhibition of disease progression in preclinical models and could be the first treatment in clinical development for Parkinson’s disease targeting α-synuclein-induced toxicity,” claims Gerard Griffioen, reMynd’s CSO. “Our Alzheimer’s tau program represents perhaps a greater potential as it addresses one of the most fundamental aspects of the disease,” adds Koen De Wite.

    ReMynd is centered on the development of disease-modifying treatments against protein misfolding disorders, with a particular focus on Parkinson and Alzheimer diseases. The firm is exploiting its expertise both through the development of an in-house drug pipeline and through the provision of contract research services for evaluating the in vivo efficacy of experimental Alzheimer treatments using validated transgenic mouse models.

    ReMynd's preclinical pipeline includes four Alzheimer disease candidates that target tau toxicity, two Parkinson disease candidates against α-synuclein toxicity, and two type 2 diabetes candidates designed to counteract islet amyloid polypeptide toxicity.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »